However, no significant difference was observed in anti-GP2 IgA antibodies in patients with CD, compared with patients with UC (P = 0.0704), HC (P = 0.0834), and non-IBD DC (P = 0.0616) (Figure 2B), although a trend of increased levels of anti-GP2 IgA was observed in patients with CD (Figure 2B). Here, CD79A is linked to inflammatory bowel disease.